Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ World https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ J&J CEO says vaccine will likely have to come with annual flu for several years

J&J CEO says vaccine will likely have to come with annual flu for several years

Johnson & Johnson Chairman and CEO Alex Gorsky spoke during an event in the South Court auditorium at the Eisenhower Executive Office building on March 10, 2021 in Washington.

Alex Wong | Getty Images

Johnson & Johnson CEO Alex Gorsky reiterated on Wednesday that people will likely need to receive additional doses of Covid-1

9 vaccines along with the annual flu for the next “several years.”

People will have to get boosted photos of Covid until the herd’s immunity is achieved globally and world leaders and scientists are able to limit the spread of highly contagious variants, Gorski told The Wall Street Journal’s Tech Health conference.

“We can look at this labeling along with the flu vaccine, probably in the next few years,” he said, referring to the Covid vaccines.

His comments come a day after US health officials called on Americans to get vaccinated so that the Delta variant, first identified in India, would not spread across the country.

The J&J vaccine requires only one stroke, unlike the Pfizer and Moderna Covid vaccines, which currently require two doses given three to four weeks apart. All three vaccines have been shown to be highly effective against Covid, although executives now say they expect strong defenses to weaken over time.

As a result, most drug manufacturers and some scientists now say people will probably need a hard shot of Covid vaccines and possibly extra shots each year, just like with seasonal flu.

BioNTech CEO Ugur Sahin told CNBC in a recent interview that researchers were seeing a drop in antibody responses to the virus after eight months.

Earlier, Gorski said people would probably have to take pictures of Covid annually.

During the magazine’s event on Wednesday, Gorski said the company is looking for new partners as it develops vaccines targeting options.

Source link